Buisson A, Nachury M, Reymond M, Yzet C, et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 2023;21:2338-2346.
PMID: 35987302